Thursday, November 19, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Minor· 25

AbbVie Bets Up to $2.54B on Disco's Next-Gen Cancer Drugs

AbbVie is teaming up with Germany's Disco Pharmaceuticals on bispecific cancer therapies, paying $40 million upfront and dangling up to $2.5 billion in milestones. The deal, announced Thursday, pushes the drugmaker deeper into next-generation treatments for solid tumors.

By the Paparazzi desk Caught by @mimi💕💕
Catcher · Bronze
November 19, 2026 · 11:45 AM · reuters.com · 1 view
Fact boxTrust 65/100 · Developing
What we verified
  • Original source: reuters.com.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.
  • The source shows no publish time. The time above is when we found it.

AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said Thursday. The structure: $40 million upfront, plus up to $2.5 billion tied to milestone payments.

The partnership targets so-called AND-gated bispecific therapeutics for solid tumors — an early-stage bet by AbbVie on next-generation bispecific therapies. Disco has been developing those AND-gated treatments for small-cell lung and colorectal cancer.

Sponsored

Disco CEO Mark Manfredi said his company will handle the research and discovery work. AbbVie, in turn, gets the right to exclusively license selected programs for further development.

Manfredi said Disco expects to pick a development candidate in the second half of next year, the next concrete checkpoint for the collaboration.

TopicsAbbVie · Disco Pharmaceuticals · Mark Manfredi

Share

Source: reuters.com

Written by AI from verified reporting.

More stories

  • Health & science 12:31 UTC · 29 minutes ago · finance.yahoo.com · 0 views
    Sanofi's next-gen rabies shot VaxRabeo scores EU approval
  • Health & science 11:45 UTC · 1 hour ago · fnob.it · 1 view
    TenK10K maps 5 million immune cells, linking DNA variants to 16 diseases
  • Health & science 11:12 UTC · 2 hours ago · trtworld.com · Caught by @pz09253 · 0 views
    France lifts bird flu alert to maximum level across mainland
  • Health & science 07:31 UTC · 5 hours ago · news24.com.au · 0 views
    Actinogen trial: Alzheimer's drug slows decline by 30pc in over-75s
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.